Altimmune (ALT) Net Cash Flow (2010 - 2026)
Altimmune (ALT) posted quarterly Net Cash Flow of $53.8 million for Q1 2026, up 342.12% year-over-year from $12.2 million in Q1 2025, and up 408.09% quarter-over-quarter from -$17.5 million in Q4 2025.
Altimmune (ALT) Net Cash Flow (2010 - 2026) Analysis & Trends
Altimmune (ALT) has reported Net Cash Flow for 17 consecutive years, with $53.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 342.12% year-over-year to $53.8 million; the TTM figure through Mar 2026 stood at $48.5 million (up 262.34% YoY), while the FY2025 annual figure was $6.8 million, up 106.96% from the prior year.
- Net Cash Flow advanced to $53.8 million in Q1 2026 per ALT's latest filing, from -$17.5 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $134.0 million in Q2 2025 and bottomed at -$121.9 million in Q3 2025.
- Historically, Net Cash Flow has averaged -$5.5 million across 5 years, with a median of -$10.4 million in 2022.
- Annual changes were most pronounced in 2022 — Net Cash Flow sank 1202.89% — and 2025, when it surged 713.28%.
- Altimmune's Net Cash Flow stood at -$16.4 million in 2022, then surged by 394.86% to $48.3 million in 2023, then sank by 88.7% to $5.5 million in 2024, then tumbled by 420.54% to -$17.5 million in 2025, then jumped by 408.09% to $53.8 million in 2026.
- Business Quant data shows ALT's Net Cash Flow at $53.8 million in Q1 2026, -$17.5 million in Q4 2025, and -$121.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Altimmune | 571.75 Mn | 571.75 Mn | - | -34.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -34.59 Mn |
| Jun 30, 2026 | -34.59 Mn |
| Mar 31, 2026 | 53.84 Mn |
| Mar 31, 2026 | 53.84 Mn |
| Dec 31, 2025 | -17.48 Mn |
| Dec 31, 2025 | -17.48 Mn |
| Sep 30, 2025 | -121.87 Mn |
| Sep 30, 2025 | -121.87 Mn |
| Jun 30, 2025 | 134.00 Mn |
| Jun 30, 2025 | 134.00 Mn |
| Mar 31, 2025 | 12.18 Mn |
| Mar 31, 2025 | 12.18 Mn |
| Dec 31, 2024 | 5.45 Mn |
| Dec 31, 2024 | 5.45 Mn |
| Sep 30, 2024 | -25.65 Mn |
| Sep 30, 2024 | -25.65 Mn |
| Jun 30, 2024 | -21.85 Mn |
| Jun 30, 2024 | -21.85 Mn |
| Mar 31, 2024 | -56.14 Mn |
| Mar 31, 2024 | -56.14 Mn |